The government alleged Dr. Bangalore billed the government payers for chemotherapy drugs he purchased from a former United Kingdom-based drug distributor that did not have a license to distribute drugs in the U.S.
One of the drugs Dr. Bangalore purchased and administered to patients was Altuzan, which is not approved by the U.S. Food and Drug Administration. The government further alleged that it tested a batch of Dr. Bangalore’s Altuzan and determined it was counterfeit and lacked the active ingredient bevacizumab.
Dr. Bangalore engaged in the alleged fraudulent activity over a two-year period that ended in May 2011, according to the DOJ.
Although Dr. Bangalore has agreed to this settlement, there has been no determination of liability in this case.
More articles on healthcare industry lawsuits:
36 recently unsealed False Claims Act cases: 5 takeaways
4 latest healthcare industry lawsuits
Patient files class-action lawsuit against UCLA Health over data breach
